RT Journal Article
SR Electronic
T1 Real-time detection of COVID-19 epicenters within the United States using a network of smart thermometers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.06.20039909
DO 10.1101/2020.04.06.20039909
A1 S.D. Chamberlain
A1 I. Singh
A1 C. Ariza
A1 A. Daitch
A1 P. Philips
A1 B. D. Dalziel
YR 2020
UL http://medrxiv.org/content/early/2020/04/10/2020.04.06.20039909.abstract
AB Containing outbreaks of infectious disease requires rapid identification of transmission hotspots, as the COVID-19 pandemic demonstrates. Focusing limited public health resources on transmission hotspots can contain spread, thus reducing morbidity and mortality, but rapid data on community-level disease dynamics is often unavailable. Here, we demonstrate an approach to identify anomalously elevated levels of influenza-like illness (ILI) in real-time, at the scale of US counties. Leveraging data from a geospatial network of thermometers encompassing more than one million users across the US, we identify anomalies by generating accurate, county-specific forecasts of seasonal ILI from a point prior to a potential outbreak and comparing real-time data to these expectations. Anomalies are strongly correlated with COVID-19 case counts and may provide an early-warning system to locate outbreak epicenters.One Sentence Summary Distributed networks of smart thermometers track COVID-19 transmission epicenters in real-time.Competing Interest StatementSDC, IS, PP, AD and CA are employees of and shareholders in Kinsa, Inc. IS conceived of and designed Kinsa products to track the spread of infectious disease. BDD has no competing financial interests. All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdfFunding StatementBDD is supported by US National Science Foundation award EEID-1911994 and by a sponsored research agreement from Kinsa, Inc. PP, CA, AD, SDC, and IS are employees and shareholders of Kinsa, Inc.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe anomaly detection and forecasting code can be accessed on GitHub, and all examples here are reproducible (https://github.com/kinsahealth/therm_anomaly_detection). https://healthweather.us/